Authors

• Sherko Küemmel
• Yan Ji (ORCID: https://orcid.org/0000-0001-9569-0574)
• Fátima Cardoso (ORCID: https://orcid.org/0000-0002-6692-2249)
• Yana Chapko
• Natalia Bolotova
• William Jacot (ORCID: https://orcid.org/0000-0001-7834-061X)
• Sudeep Gupta (ORCID: https://orcid.org/0000-0002-6742-6378)
• Lyudmila Zhukova (ORCID: https://orcid.org/0000-0003-4848-6938)
• Joseph A. Sparano (ORCID: https://orcid.org/0000-0002-9031-2010)
• Zheng Li (ORCID: https://orcid.org/0000-0002-8837-0318)
• Ana Filipa Ferreira (ORCID: https://orcid.org/0000-0003-1934-691X)
• Rama Balaraman
• Felipe Melo Cruz (ORCID: https://orcid.org/0009-0008-2795-8194)
• Wendy Chiang
• T Ahola
• Nadia Kaakiou

Institutions

• Champalimaud Foundation (PT)
• Novartis (Switzerland) (CH)
• Inserm (FR)
• Université de Montpellier (FR)
• Homi Bhabha National Institute (IN)
• College of Central Florida (US)
• Tata Memorial Hospital (IN)
• Moscow Clinical Scientific Center (RU)
• São Camilo Hospital (BR)
• IPO Porto (PT)
• Novartis (United States) (US)
• Institut de Recherche en Cancérologie de Montpellier (FR)
• Arkhangel'skiy Klinicheskiy Onkologicheskiy Dispanser (RU)
• Kliniken Essen-Mitte (DE)
• Centro Universitário São Camilo (BR)
• Tisch Cancer Institute
• Icahn School of Medicine at Mount Sinai (US)

Publication Details

Journal

JAMA Oncology

Published

2025-09-25

DOI

https://doi.org/10.1001/jamaoncol.2025.3687

Citations

3

Primary Topic

Advanced Breast Cancer Therapies

Type

article

Field-Weighted Citation Impact

4.56

Funders

• AstraZeneca
• Novartis Pharmaceuticals Corporation
• Astellas Pharma
• Daiichi Sankyo Europe